SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed...
HOLLISTON, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced that it is...
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that Eboo...
Proceeds to Be Used to Redeem All of the Outstanding 5.75% Convertible Unsecured Senior Notes This news release constitutes a...
New Drug Application for arimoclomol in NPC to be filed as early as the third quarter of 2023¹EMERYVILLE, Calif., June 22,...
Through a sponsorship agreement CCIC’s accredited Canadian Cannabis Syllabus will be made available to the medical community Avicanna Sponsors New...
ASLAN will receive up to $15 million in upfront and near-term payments and up to an additional $123.5 million based...
This is the first-ever long-duration data reported for an anti-TL1A antibodyAt the expected Phase 3 once-monthly subcutaneous dose in the...
The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the safety and efficacy of AT-001 (caficrestat) in improving or...
WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced...
VYD222 has been generally well-tolerated at all dose levels, with no serious adverse events reported to dateAs predicted by pre-clinical...
Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into...
Company Recently Reached Agreement with FDA on Design of Trial Top-line Results Expected in Mid-2024 PETACH TIKVA, Israel, June 22, 2023...
Media ReleaseCOPENHAGEN, Denmark; June 22, 2023 – Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody,...
HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
- Enrollment ongoing at multiple sites in the US, Europe, and Asia - - Multifaceted activity of serotonin-dopamine stabilizer brilaroxazine...
Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submissionRecruitment and screening update for Travelan® Controlled...
Sai Life Sciences joins SBTi Sai Life Sciences joins SBTi HYDERABAD, India, June 22, 2023 (GLOBE NEWSWIRE) -- To help...
First scientific presentation of detailed MAESTRO-NASH results confirms achievement of primary endpoints across multiple patient subgroupsNoninvasive imaging and biomarker data...
-- VASCEPA® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an Adjunct to Statin Therapy in...